Editas Medicine Inc.'s board appointed Cynthia Collins as the company's president and CEO.

Collins was serving as the genome-editing company's interim CEO since March 1.

Prior to joining Massachusets-based Editas Medicine, Collins was the CEO of Human Longevity Inc., which is building a database on human genotypes and phenotypes and using machine learning to help develop new medicines.

Collins is also a member of the board for the ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics Inc., DermTech Inc. and Biocare Medical LLC.